Validation of a Flow-Through Diffusion Cell for Use in Transdermal Research
dc.contributor.author | Addicks, William J. | en_US |
dc.date.accessioned | 2006-09-08T19:20:29Z | |
dc.date.available | 2006-09-08T19:20:29Z | |
dc.date.issued | 1987-08 | en_US |
dc.identifier.citation | Addicks, William J.; (1987). "Validation of a Flow-Through Diffusion Cell for Use in Transdermal Research." Pharmaceutical Research 4(4): 337-341. <http://hdl.handle.net/2027.42/41514> | en_US |
dc.identifier.issn | 0724-8741 | en_US |
dc.identifier.issn | 1573-904X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/41514 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3509887&dopt=citation | en_US |
dc.description.abstract | A flow-through finite-dose diffusion cell has been designed for use in transdermal drug delivery research. The diffusion cell consists of an upper donor chamber and a lower receiver compartment through which a continuous supply of fresh solvent flows. The flow is directed to an automatic fraction collector. To validate the flow-through cell, its performance was compared directly against that of a conventional single-reservoir Franz cell. Homologous alkyl p -aminobenzoates were diffused through dimethylpolysiloxane membranes, and permeability coefficients increased with increasing chain length, reaching a plateau at the butyrate ester for both types of cells. This behavior suggests a shift from membrane-controlled diffusion to boundary layer control. Permeation of the butyrate and valerate compounds was significantly faster when the flow-through cell was used, suggesting that better mixing is obtained through the flow-through cell design. Considering the advantages offered in terms of time and labor saved through its use, the flow-through cell with automatic fraction collector appears to be a viable alternative to the conventional Franz cell. | en_US |
dc.format.extent | 741897 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | Pharmacy | en_US |
dc.subject.other | Diffusion Cells | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Transdermal | en_US |
dc.subject.other | Biomedical Engineering | en_US |
dc.subject.other | Medical Law | en_US |
dc.subject.other | Biochemistry, General | en_US |
dc.subject.other | Flow-through | en_US |
dc.subject.other | Franz Cell | en_US |
dc.subject.other | Biomedicine | en_US |
dc.title | Validation of a Flow-Through Diffusion Cell for Use in Transdermal Research | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | College of Pharmacy, University of Michigan, Ann Arbor, Michigan, 48109 | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 3509887 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/41514/1/11095_2004_Article_306375.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/A:1016405506028 | en_US |
dc.identifier.source | Pharmaceutical Research | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.